Ioannou, Nikolaos <br/><br/>
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.  [electronic resource] 

 -  International journal of oncology  Mar 2016 
 - 908-18 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-2423 
<br/><br/><label>Standard No.: </label>10.3892/ijo.2016.3320  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Afatinib<br/>Antineoplastic Agents--pharmacology<br/>Cell Line, Tumor--drug effects<br/>Cell Movement<br/>Crizotinib<br/>Cyclic S-Oxides--pharmacology<br/>DNA Mutational Analysis<br/>Deoxycytidine--analogs & derivatives<br/>Drug Resistance, Neoplasm<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Inhibitory Concentration 50<br/>Ligands<br/>MAP Kinase Signaling System<br/>Mutation<br/>Pancreatic Neoplasms--metabolism<br/>Phenotype<br/>Phosphorylation<br/>Proto-Oncogene Proteins c-met--metabolism<br/>Pyrazoles--pharmacology<br/>Pyridines--pharmacology<br/>Quinazolines--pharmacology<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>STAT3 Transcription Factor--antagonists & inhibitors<br/>Signal Transduction<br/>Gemcitabine